Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of BioClinica, Inc. (“BioClinica”) (Nasdaq: BIOC) to a holding company controlled by JLL Partners, Inc. for shareholders. Under the terms of the proposed deal with an equity value of approximately $123 million, BioClinica shareholders will be entitled to receive only $7.25 in cash for each share of BIOC stock owned, well below at least one analyst’s estimated value of $9.00.
If you are an affected investor, and you want to learn more about the lawsuit or join the action, please contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, via email at WBriscoe@TheBriscoeLawFirm.com or Zach Groover at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at firstname.lastname@example.org. There is no cost or fee to you.
The BioClinica sale investigation centers on whether BioClinica’s shareholders are receiving adequate compensation for their shares in the buyout, whether the transaction undervalues BioClinica’s stock, and whether BioClinica’s board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal. Notably, at least one analyst with Yahoo! Finance estimates that the true inherent value of BioClinica could be as high as $9.00 per share. According to shareholder rights attorney Willie Briscoe, “due to the proposed sale price, the size of the deal and other factors, we believe this transaction may undervalue BioClinica’s stock. Our proposed lawsuit will seek to obtain the highest share price for all shareholders.”
The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.
Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.